1. From: Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Ann Intern Med. 2013;159(6): doi: /
Figure Legend:
Stage 3 CKD was subdivided into stages 3A and 3B (not shown). We used SAS, version 9.2 (SAS Institute, Cary, North Carolina), in our microsimulation to convert estimated GFR progression to CKD stage progression in autosomal dominant polycystic kidney disease and then used TreeAge Pro 2009 (TreeAge Software, Williamstown, Massachusetts) to do cost-effectiveness analyses. CKD = chronic kidney disease; ESRD = end-stage renal disease; GFR = glomerular filtration rate.
Date of download: 11/3/2017
Copyright © American College of Physicians. All rights reserved.